TOMI Environmental Solutions Reports 2025 Revenue Drop Amid Global Expansion Push
Event summary
- 2025 revenue declined to $5.64M from $7.74M in 2024 due to deferred capital expenditure projects amid economic uncertainty.
- Operating loss narrowed to $3.85M from $4.11M, with gross margins holding at 55%.
- International revenue grew to 29% of total sales, up from 21% in 2024, driven by healthcare sector expansion in Canada and Europe.
- Sales backlog increased to $1.8M, reflecting improved visibility into near-term revenue conversion.
- Company secured $3M in active SIS and CES integration projects, with a $500K purchase order from a global biopharmaceutical leader.
The big picture
TOMI's strategic focus on global expansion and product innovation comes amid a challenging economic environment, with deferred capital expenditure projects impacting short-term revenue. The company's efforts to penetrate the $5.29B medical device sterilization market and emerging sectors like biofuels and agricultural biosecurity position it to capitalize on long-term growth trends. However, sustaining operational efficiency and securing additional financing will be critical to executing its growth strategy.
What we're watching
- Revenue Recovery
- Whether TOMI can sustain momentum from its $20M SteraMist iHP opportunity book and $16M integration pipeline amid economic uncertainty.
- Market Penetration
- The pace at which TOMI expands in the global pharmaceutical manufacturing sector and food safety market, driven by regulatory developments.
- Financial Flexibility
- How TOMI manages its liquidity and capital access, including potential conversion of convertible notes and utilization of the $20M equity line of credit.
Related topics